Basic Research Toward Precision Medicine Using Human Lung Cancer Organoids

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K16806
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 50020:Tumor diagnostics and therapeutics-related
• Research Institution: Wakayama Medical University
• Principal Investigator: Jun Oyanagi 和歌山県立医科大学, バイオメディカルサイエンスセンター, 助教 (80716069)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: オルがノイド / 肺がん

Outline of Final Research Achievements

Organoids were successfully established by culture using specimens provided by patients who underwent bronchoscopic biopsy at the Internal Medicine III, Wakayama Medical University. The cultured organoids were transplanted into immunodeficient mice, and tumorigenicity was confirmed. Next-generation sequencing analysis revealed that the driver gene mutations detected in the clinical test were also detected in the organoids, indicating that the organoids established in this study were derived from the patient's tumor cells. Furthermore, drug evaluation of organoids established from patients showing resistance to erlotinib and osimertinib revealed resistance to both drugs as well as drugs that could overcome it.

Free Research Field

腫瘍生物学

Academic Significance and Societal Importance of the Research Achievements

個別化医療の実現を実現するためには、各患者由来のがん細胞を詳細に解析することが必
須である。しかしながら、がん組織からの細胞株化効率が低い事が大きな障壁となっている。また、肺がんは進行期で発見されることが多く、また生検の侵襲性が高いため、繰り返し検体を採取することが困難である。本研究では気管支鏡生検検体よりオルガノイドを樹立することに成功した。本研究の試みから、治療に伴う薬剤耐性獲得時のオルガノイドを樹立することで、治療抵抗性の克服の探索をはじめ、創薬等への応用が期待される。